World J Mens Health. 2020 Apr;38(2):178-190. doi: 10.5534/wjmh.190006. Epub 2019 Jun 04.
Testosterone and Dehydroepiandrosterone Treatment in Ageing Men: Are We All Set?.
The world journal of men's health
Andreas Walther, Julian Seuffert
Affiliations
Affiliations
- Department of Biological Psychology, TU Dresden, Dresden, Germany.
- Department of Clinical Psychology and Psychotherapy, University of Zurich, Zurich, Switzerland.
- Task Force on Men's Mental Health of the World Federation of the Societies of Biological Psychiatry (WFSBP). [email protected].
PMID: 31190486
PMCID: PMC7076306 DOI: 10.5534/wjmh.190006
Abstract
Although demographic statistics show that populations around the world are rapidly ageing, this rising life expectancy is accompanied by an increase in the number of people living with age-related chronic conditions, such as frailty, cognitive decline, depression, or sexual dysfunction. In men, a progressive decline in androgens occurs with increasing age, and low androgen levels are associated with age-related chronic conditions. However, androgen administration studies are inconclusive, showing differing results according to the androgen used (testosterone [T], dehydroepiandrosterone [DHEA]), the group of men examined (younger vs. older; eugonadal vs. hypogonadal) and the conditions studied (frailty, cognitive decline, depression, sexual dysfunction). In this review, the current state for the use of T and DHEA therapy in men for the age-related conditions is examined. Due to the progressive age-related decline in androgens leading to a higher rate of older men having low androgen levels, the effects of androgen treatment in elderly males will be of particular interest in this review. Dose-response relationships, the role of potential moderators, and the androgen treatment-related risk for adverse events will be discussed. Studies have suggested that T treatment - more so than DHEA treatment - may be an effective therapy against age-related chronic conditions in men with low T levels; especially older men. Such conditions include frailty, depression, or sexual dysfunction. However, T treatment does not emerge as an effective therapy against cognitive decline. Nevertheless, more high-quality, randomised controlled trials using T treatment for age-related chronic conditions are necessary if further conclusions are to be made.
Copyright © 2020 Korean Society for Sexual Medicine and Andrology.
Keywords: Aging; Dehydroepiandrosterone; Healthy aging; Men; Morbidity; Testosterone
Conflict of interest statement
Dr. Walther and M.Sc. Seuffert are exclusively employed by the TU Dresden as research assistants and have no potential conflicts of interest to disclose.
References
- Lancet. 2016 May 21;387(10033):2145-2154 - PubMed
- Eur Neuropsychopharmacol. 2013 Aug;23(8):910-8 - PubMed
- Urology. 2006 Sep;68(3):626-30 - PubMed
- J Urol. 1994 Jan;151(1):54-61 - PubMed
- Am J Geriatr Psychiatry. 2013 Nov;21(11):1154-63 - PubMed
- J Clin Endocrinol Metab. 2004 Feb;89(2):503-10 - PubMed
- Psychoneuroendocrinology. 2018 Dec;98:139-147 - PubMed
- Aging (Albany NY). 2011 May;3(5):533-42 - PubMed
- J Am Geriatr Soc. 2011 May;59(5):814-21 - PubMed
- Psychoneuroendocrinology. 2018 Mar;89:7-12 - PubMed
- JAMA. 2018 Oct 2;320(13):1321-1322 - PubMed
- Lancet. 2009 Oct 3;374(9696):1196-208 - PubMed
- Mayo Clin Proc. 2016 Jul;91(7):881-96 - PubMed
- Arch Intern Med. 2006 Jan 23;166(2):207-12 - PubMed
- J Sex Med. 2014 Jun;11(6):1577-92 - PubMed
- Am J Mens Health. 2017 May;11(3):737-747 - PubMed
- Age (Dordr). 2013 Jun;35(3):963-71 - PubMed
- PLoS One. 2014 Jan 29;9(1):e85805 - PubMed
- J Clin Endocrinol Metab. 2010 Jul;95(7):3165-72 - PubMed
- Neurology. 2005 Jun 28;64(12):2063-8 - PubMed
- Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4279-84 - PubMed
- Clin Endocrinol (Oxf). 1998 Oct;49(4):421-32 - PubMed
- BMJ Open. 2017 Nov 16;7(11):e015284 - PubMed
- Eur Urol. 2017 Dec;72(6):1000-1011 - PubMed
- Clin Endocrinol (Oxf). 2005 Oct;63(4):381-94 - PubMed
- J Androl. 2007 Nov-Dec;28(6):875-82 - PubMed
- Neurology. 2001 Jul 10;57(1):80-8 - PubMed
- J Gerontol A Biol Sci Med Sci. 2013 Oct;68(10):1236-42 - PubMed
- Osteoporos Int. 2009 Jul;20(7):1131-40 - PubMed
- Clin Endocrinol (Oxf). 2018 Jan;88(1):88-95 - PubMed
- Arch Neurol. 2006 Feb;63(2):177-85 - PubMed
- Eur J Endocrinol. 2013 Feb 20;168(3):445-55 - PubMed
- J Clin Endocrinol Metab. 1999 Oct;84(10):3681-5 - PubMed
- Neuropsychology. 2013 May;27(3):356-363 - PubMed
- J Am Geriatr Soc. 2004 Jan;52(1):80-5 - PubMed
- J Sex Med. 2012 Aug;9(8):2093-103 - PubMed
- JAMA. 2017 Feb 21;317(7):717-727 - PubMed
- Dtsch Med Wochenschr. 2018 Sep;143(19):1405-1416 - PubMed
- Am J Psychiatry. 2006 Jan;163(1):59-66 - PubMed
- Am J Alzheimers Dis Other Demen. 2015 Jun;30(4):421-30 - PubMed
- JAMA. 2008 Jan 2;299(1):39-52 - PubMed
- Steroids. 1999 Sep;64(9):640-7 - PubMed
- J Am Coll Cardiol. 1990 Nov;16(6):862-70 - PubMed
- J Clin Endocrinol Metab. 1997 Aug;82(8):2386-90 - PubMed
- J Urol. 2015 Sep;194(3):759-60 - PubMed
- JAMA Intern Med. 2017 Apr 1;177(4):471-479 - PubMed
- Health Econ. 2017 May;26(5):582-599 - PubMed
- Arch Gen Psychiatry. 2000 Feb;57(2):141-7; discussion 155-6 - PubMed
- Urology. 2004 Apr;63(4):641-6 - PubMed
- Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1567-71 - PubMed
- J Clin Psychopharmacol. 2009 Jun;29(3):216-21 - PubMed
- J Clin Psychopharmacol. 2005 Dec;25(6):584-8 - PubMed
- J Urol. 2016 Mar;195(3):699-705 - PubMed
- Urology. 2005 Sep;66(3):597-601 - PubMed
- Int J Impot Res. 2008 Jul-Aug;20(4):378-87 - PubMed
- Psychoneuroendocrinology. 2016 Feb;64:57-65 - PubMed
- J Clin Endocrinol Metab. 2002 Feb;87(2):589-98 - PubMed
- J Clin Psychopharmacol. 2004 Aug;24(4):379-85 - PubMed
- Mayo Clin Proc. 2007 Jan;82(1):20-8 - PubMed
- Ageing Res Rev. 2011 Sep;10(4):430-9 - PubMed
- J Clin Endocrinol Metab. 2016 Aug;101(8):3096-104 - PubMed
- Oncotarget. 2016 Sep 20;7(38):60844-60857 - PubMed
- Lancet. 2013 Oct 26;382(9902):1405-12 - PubMed
- J Appl Physiol (1985). 1999 Dec;87(6):2274-83 - PubMed
- J Clin Endocrinol Metab. 2014 Oct;99(10):3821-8 - PubMed
- J Clin Endocrinol Metab. 1999 Jun;84(6):1966-72 - PubMed
- J Clin Endocrinol Metab. 2000 Aug;85(8):2670-7 - PubMed
- Cochrane Database Syst Rev. 2000;(2):CD000304 - PubMed
- Psychoneuroendocrinology. 2019 Jul;105:64-78 - PubMed
- J Clin Endocrinol Metab. 2018 May 1;103(5):1715-1744 - PubMed
- Urol Res. 2001 Aug;29(4):278-81 - PubMed
- JAMA Psychiatry. 2019 Jan 1;76(1):31-40 - PubMed
- J Gerontol A Biol Sci Med Sci. 2005 Mar;60(3):385-90 - PubMed
- Am J Psychiatry. 1999 Apr;156(4):646-9 - PubMed
- N Engl J Med. 2006 Oct 19;355(16):1647-59 - PubMed
- Anat Rec. 1978 Dec;192(4):513-8 - PubMed
- J Clin Endocrinol Metab. 2013 Sep;98(9):3615-26 - PubMed
- J Sex Med. 2013 Jun;10(6):1612-27 - PubMed
- JAMA. 2013 Nov 6;310(17):1829-36 - PubMed
- J Clin Endocrinol Metab. 1997 Jul;82(7):2363-7 - PubMed
- J Clin Endocrinol Metab. 2016 May;101(5):2201-10 - PubMed
- Eur J Endocrinol. 2016 Mar;174(3):R99-116 - PubMed
- Psychoneuroendocrinology. 2016 Feb;64:40-6 - PubMed
- Aging Male. 2009 Dec;12(4):104-12 - PubMed
- Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006221 - PubMed
- J Sex Med. 2018 Jun;15(6):820-838 - PubMed
- Psychopharmacology (Berl). 2006 Nov;188(4):541-51 - PubMed
- N Engl J Med. 2016 Feb 18;374(7):611-24 - PubMed
- J Gerontol A Biol Sci Med Sci. 2004 Jan;59(1):75-8 - PubMed
- J Am Geriatr Soc. 2008 Jul;56(7):1292-8 - PubMed
- Maturitas. 2005 Feb 14;50(2):124-33 - PubMed
- Am J Psychiatry. 2003 Jan;160(1):105-11 - PubMed
- J Sex Med. 2014 Jan;11(1):230-9 - PubMed
- Arch Gen Psychiatry. 2005 Feb;62(2):154-62 - PubMed
- Am J Physiol Endocrinol Metab. 2002 Aug;283(2):E284-94 - PubMed
- J Sex Med. 2010 Jul;7(7):2572-82 - PubMed
- CNS Neurol Disord Drug Targets. 2018;17(9):706-711 - PubMed
- Psychoneuroendocrinology. 1998 Aug;23(6):617-29 - PubMed
- J Gerontol A Biol Sci Med Sci. 2001 May;56(5):M266-72 - PubMed
Publication Types